Effect of short-term interferon-β treatment on cytokines in multiple sclerosis: significant modulation of IL-17 and IL-23.
Therapeutic effect of interferon-β (IFN-β) treatment has been associated with modulation of the balance between Th1, Th17, Th2 and regulatory T (Treg) cells, whereas the impact of disease modifying drugs on Th9-immunity in multiple sclerosis (MS) has not been studied. To investigate the short-term effects of IFN-β treatment on cytokines in MS, we determined serum levels of IL-17, IL-23, IL-10, IL-4, IFN-γ, IL-9 and TGF-β in relapsing remitting MS patients before and 2 months after IFN-β treatment by ELISA. MS patients showed increased IL-17, IL-23 and IL-4 levels and decreased IL-9 levels as compared to healthy controls. IFN-β treatment only reduced IL-17 and IL-23 levels, whereas the levels of other cytokines remained unchanged. IFN-β treatment appears to exert its earliest therapeutic effect on Th17-immunity. The influence of IL-9 on MS pathogenesis needs to be further studied.
Department of Neurology, Acıbadem University School of Medicine, Istanbul, Turkey.
Murat
M
Kürtüncü
Erdem
E
Tüzün
Recai
R
Türkoğlu
Belgin
B
Petek-Balcı
Sema
S
Içöz
Münevver
M
Pehlivan
Ömer
Ö
Birişik
Canan
C
Ulusoy
Erkingül
E
Shugaiv
Gülşen
G
Akman-Demir
Mefküre
M
Eraksoy
D000328:Adult; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D007109:Immunity / Q000187:drug effects; D016899:Interferon-beta / Q000494:pharmacology* / Q000627:therapeutic use*; D020381:Interleukin-17 / Q000276:immunology*; D053759:Interleukin-23 / Q000276:immunology*; D008297:Male; D009103:Multiple Sclerosis / Q000188:drug therapy* / Q000276:immunology*; D058504:Th17 Cells / Q000187:drug effects / Q000276:immunology; D013997:Time Factors
D020381:Interleukin-17; D053759:Interleukin-23; D016899:Interferon-beta